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The efﬁcacy of chemotherapy in pediatric acute lymphoblastic leukemia (ALL) patients has
signiﬁcantly increased in the last 20 years; as a result, the focus of research is slowly
shifting from trying to increase survival rates to reduce chemotherapy-related toxicity. At
the present time, the cornerstone of therapy for ALL is still formed by a reduced number
of drugs with a highly toxic proﬁle. In recent years, a number of genetic polymorphisms
have been identiﬁed that can play a signiﬁcant role in modifying the pharmacokinetics and
pharmacodynamics of these drugs. The best example is that of the TPMT gene, whose
genotyping is being incorporated to clinical practice in order to individualize doses of mer-
captopurine. However, there are additional genes that are relevant for the metabolism,
activity, and/or transport of other chemotherapy drugs that are widely use in ALL, such
as methotrexate, cyclophosphamide, vincristine, L-asparaginase, etoposide, cytarabine, or
cytotoxic antibiotics. These genes can also be affected by genetic alterations that could
therefore have clinical consequences. In this review we will discuss recent data on this
ﬁeld, with special focus on those polymorphisms that could be used in clinical practice to
tailor chemotherapy for ALL in order to reduce the occurrence of serious adverse effects.
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INTRODUCTION
In the last 20 years, the chemotherapy treatment of pediatric acute
lymphoblastic leukemia (ALL), the most common malignancy in
children, has reached success rates of up to 90%. This achieve-
ment has allowed limiting the administration of damaging cranial
irradiation to rare cases with central nervous system (CNS) inﬁl-
tration (Laningham et al., 2007). However, the clinical routine of
chemotherapy treatments in these patients includes intrathecal
and high intravenous doses of various drugs with a highly toxic
proﬁle. This is therefore a source of awide variety of complications
that add up to those caused by peripheral blood cell depression or
the disease itself (Vagace and Gervasini, 2011). In fact, the toxicity
of chemotherapy is a common cause of morbidity and mortality
in children with ALL, as well as a frequent source of sequelae at
mid-long term. These adverse effects are often the consequence of
direct toxicity in healthy tissue, as a result of the low speciﬁcity
displayed by these drugs and become more frequent as the treat-
ment is intensiﬁed. In particular, central neurotoxicity is a major
clinical concern in pediatric patients (Vagace et al., 2012).
In this scenario, it is obvious that any factor able to modify
either the pharmacokinetics or pharmacodynamics of chemother-
apy drugs holds the potential to be critical for the occurrence of
serious adverse effects in ALL patients. One such factor is the
presence of genetic polymorphisms in genes coding for drug-
metabolizing enzymes, transporters, or drug targets. Genetic
association studies in this ﬁeld have traditionally been focused
on efﬁcacy parameters in general and survival in particular and
therefore the body of work on the association with toxicity is still
scarce.
In this reviewwewill summarizewhat is currently known about
how genetic variability can affect the toxicity induced by the main
drugs used in the chemotherapy of ALL (see summary in Table 1).
A special focus will be put on the discussion on those genetic
analyses with the potential to tailor chemotherapy regimes in the
ALL setting.
L-ASPARAGINASE
L-asparaginase is a standard component in the initial treatment
of childhood ALL which induces the depletion of the essential
amino acid L-asparagine in the tumor cells resulting in inhibition
of protein synthesis.
This drug has been related to serious adverse effects in ALL
patients, such as acute pancreatitis (Flores-Calderon et al., 2009)
or cerebrovascular accidents (Gugliotta et al., 1992). In addition,
hypersensitivity reactions occur in up to 25% of the patients
and 10% of those may experience life-threatening anaphylactic
reactions (Cortijo-Cascajares et al., 2012). Studies on the phar-
macogenetics of asparaginase in ALL are in their early stages.
A large study recently carried out at St Jude Children’s Hospi-
tal by Chen et al. (2010) interrogated more than 500 000 single
nucleotide polymorphisms (SNPs) in 485 children with ALL and
found that ﬁve mutations (rs4958351, rs10070447, rs6890057,
rs4958676, and rs6889909) in theGRIA1 genewere associatedwith
the occurrence of hypersensitivity to the drug. GRIA1 encodes
a subunit of the AMPA receptor, a tetrameric ligand-gated ion
channel that transmits glutamatergic signals in the brain. Glu-
tamate not only has a role as a neurotransmitter, but also as
an immunomodulator (Pacheco et al., 2007) and the study by
www.frontiersin.org November 2012 | Volume 3 | Article 249 | 1
“fgene-03-00249” — 2012/11/20 — 21:12 — page 2 — #2
Gervasini and Vagace Genetic polymorphisms in acute leukemia
Table 1 | Summary of genes and polymorphisms with a putative relevant role in chemotherapy-induced toxicity in acute lymphoblastic leukemia
Gene Polymorphism Drug affected; main effect Reference
ABCB1 C3435T, G2677T/A, C1236T IMTa; Less common toxicity-related dose reduction Gurney et al. (2007)
CYP2B6 *2A, *4 CFDb; Hemorrhagic cystitis, oral mucositis Rocha et al. (2009)
DCK Several SNPs Ara-Cc; higher susceptibility to drug effects Hartford et al. (2009)
DHFR 19-bp deletion MTXd, hepatotoxicity Ongaro et al. (2009)
GRIA1 Several SNPs ASP; higher risk of hypersensitivity Chen et al. (2010)
ITPA c.94C > A 6-MP; fever, hepatotoxicity Stocco et al. (2009), Wan Rosalina et al. (2011)
ITPA IVS + 21A > C 6-MP; higher risk of myelotoxicity Hawwa et al. (2008)
MTHFR C677T MTX; neurotoxicity, hepatotoxicity, myelosuppression Strunk et al. (2003), Mahadeo et al. (2010),
D’Angelo et al. (2011), Yang et al. (2012)
MTHFR A1298C MTXe, hematological toxicity Kantar et al. (2009)
MTRR A66G MTX, oral mucositis Huang et al. (2008)
RFC1 G-80A MTX, overall toxicity Shimasaki et al. (2006), Imanishi et al. (2007)
TPMT *2, *3A, *3C 6-MP; Acute hematopoietic toxic effects McLeod et al. (1999), Weinshilboum (2001),
Pui et al. (2004)
aOnly data on chronic myeloid leukemia patients are available; bSeveral types of leukemia were included in the study; cPreliminary data on cell lines; dAdult patients;
eControversial association.
6-MP, 6-mercaptopurine; MTX, methotrexate; ASP, L-asparaginase; CFD, cyclophosphamide; Ara-C, cytosine arabinoside; IMT, imatinib
Chen et al. (2011) provides the ﬁrst link between GRIA1 polymor-
phisms and an immune-related phenotype such as the occurrence
of hypersensitivity to L-asparaginase. A later genome-wide study
by the same group using the HapMap lymphoblastoid cell lines
tested more than 2 million SNPs and identiﬁed the aspar-
tate metabolic routes as the most likely candidate pathway for
asparaginase sensitivity.
Finally, polymorphisms in other genes that mediate the
antileukemic effect of asparaginase, such as the asparaginase syn-
thetase gene (ASNS), the basic region leucine zipper activating
transcription factor 5 (ATF5), or the argininosuccinate synthase 1
(ASS1), have been associated to lower event-free survival of ALL
patients, albeit the authors reported no associations with adverse
effects (Rousseau et al., 2011).
CYCLOPHOSPHAMIDE
Cyclophosphamide, an oxazophosphorine, bifunctional DNA
alkylating agent, is crucial in the treatment of most pediatric
and adult malignancies, including ALL. Cyclophosphamide is
bioactivated in the liver by various enzymes of the hepatic
P450 system including CYP2A6, CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP3A4, and CYP3A5 (Cox, 1979; Parekh and Sladek,
1993; Dirven et al., 1994; Hayes and Pulford, 1995; Ludeman,
1999; Huang et al., 2000), whilst detoxiﬁcation of active metabo-
lites is mainly mediated by aldehyde dehydrogenases (ALDH1A1
and ALDH3A1; Parekh and Sladek, 1993) and glutathione S-
transferases (GSTA1, GSTM1, GSTP1, and GSTT1; Hayes and
Pulford, 1995). These enzymes are known to have functional
polymorphisms, some of which have been found to impact toxi-
city associated with cyclophosphamide-based therapies in several
pathologies (Zhong et al., 2006; Cho et al., 2010).
A study conducted in patients with leukemia who underwent
hematopoietic stem cell transplantation showed that carriers of
CYP2B6*2A or CYP2B6*4 variant alleles treated with cyclophos-
phamide were at higher risk of developing hemorrhagic cystitis
and oral mucositis, respectively (Rocha et al., 2009). Interestingly,
at least theCYP2B6*4 variant has been related to increased enzyme
activity (Lang et al., 2001; Kirchheiner et al., 2003), and presum-
ably this could lead to increased bioactivation of the drug and
therefore could explain the observed higher incidence of toxi-
city in the patients. Numerous other CYP2B6 alleles that have
been associated with changes in the enzyme activity/expression
(www.cypalleles.ki.se/cyp2b6.htm) and therefore they could be
relevant with regard to cyclophosphamide-induced side effects.
It should also be remarked that the CYP2B6 gene exhibits a large
intraethnic variability. Indeed, novel allelic variants and differ-
ent linkage disequilibrium values have been described in certain
populations (Restrepo et al., 2011), which should be taking into
account when implementing tailored genotyping protocols aimed
to determine the potential of CYP2B6 as a biomarker of drug
response.
Allan et al. (2001) have reported that the 105Val allele of the
GSTP1 Ile105Val polymorphism was overrepresented in a group
of patients with therapy-related acute myeloid leukemia. Inter-
estingly, this association was only observed in therapies includ-
ing GSTP1 substrates such as cyclophosphamide. The authors
hypothesized that an overexposure to the drug due to reduced
detoxiﬁcation capabilities could have played a role in leukemo-
genesis. Moreover, the same variation of the GSTP1 gene has
been suggested to be one of the factors determining a higher neu-
rotoxicity of ifosfamide, a closely related agent (Zielinska et al.,
2005). A later report showed that the presence of the 677C-1298C
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haplotype in the methylenetetrahydrofolate reductase (MTHFR)
gene was also associated to secondary acute myeloid leukemia
after cyclophosphamide treatment of hematologic malignancies
(Guillem et al., 2007).
Other polymorphisms reportedly associated with increased
cyclophosphamide-induced toxicity areCYP2C19*2 (Takada et al.,
2004; Ngamjanyaporn et al., 2011), CYP3A4*1B (Su et al., 2010),
GSTM1/T1 null (Cho et al., 2010), ALDH3A1*2 and ALDH1A1*2
(Ekhart et al., 2008), ABCC4 rs9561778 (Low et al., 2009), or
ABCG2 Q141K (rs2231142; Kim et al., 2008). It should be stated
that some of these studies were conducted in patients with hema-
tological malignancies but there are as yet no available data
on ALL.
Cyclophosphamide is a chemotherapeutic agent used in a
broad array of malignancies, which somewhat hampers the repro-
ducibility of these ﬁndings. Therefore, larger studies and more
consistent populations are needed in order to unequivocally
establish the impact of the aforementioned SNPs and to iden-
tify other variants that could account for increased toxicity in
cyclophosphamide-based therapies in ALL.
CYTOSINE ARABINOSIDE
Cytosine arabinoside (Cytarabine, Ara-C) is an antimetabolite
widely used in acute leukemia, which is associated with sev-
eral adverse side effects, including myelosuppression, infections,
mucositis, neurotoxicity, and acute pulmonary syndrome (Hart-
ford et al., 2009). Candidate gene approaches have been used
to identify genetic variables that are important in susceptibility
to Ara-C. These studies have mainly focused on genes in the
pharmacokinetic pathway of the drug. For instance, a common
polymorphism, A79C (rs2072671), in the cytidine deaminase
(CDA) gene, which catalyzes the rapid deamination of Ara-C,
results in lower enzyme activity and hence a decreased rate of
Ara-C metabolism (Kirch et al., 1998). Interestingly, Bhatla et al.
(2009) have shown that Ara-C-related mortality was signiﬁcantly
elevated in carriers of the 79CC genotype in children with acute
leukemia. Moreover, Ciccolini et al. (2012) have related this SNP to
life-threatening toxicities induced in a girl with lymphoma treated
with Ara-C.
Hartford et al. (2009) utilized an unbiased whole-genome
approach to ﬁnd polymorphisms that might predict the suscepti-
bility to the cytotoxic effects of Ara-C in cell lines derived from
persons of European (CEU) and African (YRI) ancestry. The
authors identiﬁed a unique pharmacogenetic signature consisting
of four SNPs explaining 51% of the variability in sensitivity to ara-
C among the CEU and ﬁve SNPs explaining 58% of the variation
among the YRI. These unique genetic signatures comprised novel
target genes, most importantly GIT1, RAD51AP1, and SLC25A37,
which can be studied further in functional studies. Furthermore,
the authors examined 64 SNPs in the deoxycytidine kinase gene
(DCK), which catalyzes the most essential step in the Ara-C acti-
vation pathway. Their conclusions show that cells that carried the
DCK A70G (Ile24Val) polymorphism, which affects protein func-
tion, had an increased sensitivity to Ara-C (Hartford et al., 2009).
In this regard, a later studyhas suggested that anotherDCK SNP,C-
360G, is associatedwith the occurrence of mucositis after low-dose
Ara-C in pediatric ALL patients (Banklau et al., 2010).
Recently, a studybyXuet al. (2012) seems to conﬁrm the impor-
tance of both CDA and DCK genes as important loci that should
be further investigated regarding the outcome of Ara-C-based
chemotherapy in leukemia patients.
CYTOTOXIC ANTIBIOTICS
Doxorubicin (adriamycin) and daunorubicin (daunomycin) are
anthracycline antibiotics commonly used in the treatment of
leukemias whose main concern is their well-known dose-related
cardiotoxicity (Gilladoga et al., 1976).
The contribution of pharmacogenetic factors across the dox-
orubicin biochemical pathway is not well established, but the drug
is characterized by inter-individual variation in pharmacokinetic
and pharmacodynamic parameters, and genetic variation has been
suggested to account for at least part of this variability (Jamieson
andBoddy, 2010; Lal et al., 2010). For instance, SNPs in theABCB1
and SLC22A16 transporter genes have been shown to increase
exposure levels that could result in a higher incidence of adverse
effects (Lal et al., 2007, 2008). No studies on the impact of these
mutations on the incidence of adverse effects in ALL patients have
as yet been conducted. In patients of breast cancer treated with
doxorubicin, Bray et al. (2010) have shown that several SNPs in the
SLC22A16 inﬂux transporter gene (A146G, T312C, and T755C)
are related to lower incidence of dose delay, indicative of less toxi-
city; although it should be noted that the authors considered their
own ﬁndings as preliminary.
In addition, in vitro studies have shown that the wild-type allele
of the Val88Ile (262G>A, rs1143663) SNP in the carbonyl reduc-
tase 1 (CBR1) gene, involved in doxorubicin metabolism, exhibits
a higher rate of synthesis of cardiotoxic metabolites (Gonzalez-
Covarrubias et al., 2007). The conclusions of this work seem to
indicate that the small percentage of individuals of African ances-
try (to which this SNP is conﬁned) who are homozygous for the
low-activity Ile88 allele would therefore be at lower risk of car-
diotoxicity. Paradoxically, this would imply that a majority of
the African population is at-risk for doxorubicin-induced toxi-
city. Interestingly enough, a study by Hasan et al. (2004) evaluated
100AfricanAmerican patients who underwent doxorubicin-based
combination therapy and found that they appeared to suffer car-
diotoxicity from doxorubicin three times more frequently than
previously studied populations. Because of the low sample size
analyzed and the lack of head-to-head comparison, larger studies
in a multiracial setting seem necessary to clarify this ﬁnding.
With regard to daunorubicin, a recent work has shown a
trend toward signiﬁcant increase in the drug systemic exposure
in patients carrying the C-allele of the CBR1 G312C (Leu73Leu,
rs25678) polymorphism, which could elevate the risk of drug-
induced toxicity (Varatharajan et al., 2012). In any case, it
should be stated that the genetic associations reported for these
two anthracyclines are still relatively recent and have not been
consistently observed yet.
Mitoxantrone is an anthracycline analog which is a known sub-
strate for ABC efﬂux transporters such as those encoded by the
ABCB1 and ABCG2 genes (Kodaira et al., 2010). To date, there
are no studies in the ALL setting testing the plausible hypothesis
that genetic polymorphisms in these genes could affect mitox-
antrone disposition and hence modulate the response and side
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effects to the drug. However, Cotte et al. (2009) have determined
the frequencies of seven ABCB1 and ABCG2 SNPs in multiple
sclerosis patients treated with mitoxantrone. Several associations
were reported regarding the clinical response rate, but no relevant
differences in genotype frequencies were observed in a subset of
patients with severe hematological or cardiac side effects. How-
ever, it was intriguing that one patient presenting cardiomyopathy
after a low dose of mitoxantrone was found to carry an uncom-
mon genotype with homozygous variant alleles in two ABCB1
(G2677T/A, rs2032582 and C3435T, rs1045642) and one ABCG2
locus (Gln141Lys, rs2231142), in addition to a variant allele for
the ABCC2 C-24T (rs717620) SNP (Cotte et al., 2009).
ETOPOSIDE
Etoposide is a topoisomerase II inhibitor used in a variety of
malignancies. This drug is a substrate for the P-glycoprotein trans-
porter, CYP3A4 andCYP3A5 isoforms (Relling et al., 1994), whose
expression is partly regulated by the vitamin D receptor (VDR;
Drocourt et al., 2002), and a number of phase II metabolizing
enzymes, including GSTs and UGT1A1 (Watanabe et al., 2003).
Therefore, alterations in these genes hold the potential to be rel-
evant for the drug concentrations and clinical effects. However,
to our knowledge there are as yet no studies investigating the
association of polymorphisms in the etoposide pathways with the
occurrence of adverse effects, mainly dose-limiting myelosuppres-
sion, in patients treated with the drug. Currently, there are only
indications based on the impact of these genetic variations on
the level of exposure to the drug. For instance, a study in 109
children diagnosed with ALL showed that carriers of both the
CYP3A5*3/*3 and GSTP1 Ile/Ile genotype displayed a lower drug
clearance, although this association was only observed in African
Americans one month after treatment (Kishi et al., 2004). More-
over, the ABCB1 C3435T SNP was found to be an independent
predictor of etoposide clearance disregarding ethnicity. In con-
trast, one year after treatment, the UGT1A1 6/6 (*1/*1), VDR
intron 8 GG and VDR Fok 1 CC genotypes predicted higher clear-
ance inAfricanAmericans (Kishi et al., 2004). Despite that thedrug
pharmacokinetics were shown to correlate with the incidence of
adverse effects, no analyses of the association between SNPs and
toxicity were conducted by the authors (Kishi et al., 2004).
Two genome-wide studies by an American research group have
identiﬁed both genomic regions and SNPs associated with cel-
lular sensitivity to etoposide. Huang et al. (2007) identiﬁed 63
genetic variants that contributed to etoposide-induced cytotoxi-
city through the evaluation of cell growth inhibition in cell lines
from multi-generational pedigrees. The variants were present in
genes whose expression had previously been related to altered cell
sensitivity to etoposide, such as AGPAT2, IL1B, and WNT5B, but
also in other genes not yet known to be associated with sensitivity
to this agent. A limitation of this study was that candidate genes
known to contribute to the pharmacokinetics of etoposide, e.g.,
CYP3A, UGT1A1, and ABCB1, are not expressed or are expressed
at very low levels in the lymphoblastoid cell lines utilized.
Using the same cell models, Bleibel et al. (2009) later identiﬁed
22 unique SNPs in four genes among three chromosomes sig-
niﬁcantly associated with cytotoxic phenotypes at one or more
treatment conditions. Genes implicated were UVRAG, a DNA
repair gene, SEMA5A, which encodes semaphoring-5A protein
involved in axonal guidance during development, the SLC7A6
transporter gene, which participates in nitric oxide synthesis that
ultimately induces apoptosis and PRMT7, encoding the protein
arginine methyltransferase that catalyzes an irreversible protein
modiﬁcation. All these processes would be altered in the presence
of functional polymorphisms and could presumably lead to the
observed increased cytotoxicity in etoposide-treated cells.
Unfortunately, and despite the interesting background pro-
vided by these two genome-wide reports, there are as yet no clinical
studies that have investigated the role of any of the aforementioned
genetic variants in patients treated with etoposide.
IMATINIB
Imatinib is a Bcr-Abl tyrosine kinase inhibitor that is speciﬁcally
used in the treatment of Phy + leukemia. The drug is demethy-
lated to N-desmethyl-imatinib by CYP3A4/5, with other CYP450
isoforms playing a less important role (Peng et al., 2005). Indeed,
coadministration of inhibitors and inducers of CYP3A activity
results in signiﬁcant modiﬁcations of the drug’s pharmacokinetics
(Bolton et al., 2004), which show a wide interindividual variability
(Judson et al., 2005). In order to explain this variability, pharmaco-
genetics studies have been carried out to ﬁnd genetic determinants
that could modify the pharmacological response to the drug. Most
of these studies have aimed to ﬁnd genetic markers of resistance.
Thus, a number of polymorphisms in genes coding for trans-
porters (ABCB1, ABCG2, SLC22A1), drug metabolizing enzymes
(CYP3A5), proteins with involved in the nucleotide excision repair
pathway (EERC) and proteins related to leukemogenesis (SOCS1
and PTPN22) have been associated to the efﬁcacy of the treat-
ment (Dulucq and Krajinovic, 2010; Kong et al., 2012; Vivona
et al., 2012). These studies have mainly been conducted in patients
with chronic myeloid leukemia (CML) and gastrointestinal stro-
mal tumors (GIST), probably because of the higher incidence of
these two diseases.
On the other hand, pharmacogenetic studies on imatinib-
related toxicity are scarce and therefore the clinical impact of
genetic polymorphisms on the occurrence of adverse effects has to
be inferred from their effect on the drug blood levels, as it has been
reported that the severity of the side effects seems to correlate with
the drug’s pharmacokinetics (Judson et al., 2005). In this regard,
two studies have shown a reduced oral clearance of the drug in
patients carrying the CYP2D6*4 (Gardner et al., 2006) or ABCG2
421A variant alleles (Petain et al., 2008), which could hypotheti-
cally result in increased adverse effects. Interestingly, Gurney et al.
(2007) reported a higher drug clearance but also a less common
toxicity-related dose reduction in CML patients on imatinib who
were carriers of the TT genotype at each of three key positions in
the ABCB1 gene (1236, 2677, and 3435).
These data are not yet sufﬁciently conclusive to translate into
individual drug dose adjustments and therefore further studies
are still needed to analyze other genetic variants that can help
individualize imatinib therapy.
MERCAPTOPURINE
6-Mercaptopurine (6-MP) is an antimetabolite that has been
used for 40 years in the treatment of a variety of diseases. In
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particular, 6-MP in orally daily regimen associated with weekly
methotrexate (MTX) is the backbone of maintenance chemother-
apy for ALL. The drug is metabolized toward active, and toxic,
6-thioguanine nucleotides (6-TGN) that are responsible for the
elevated myelotoxicity of this chemotherapy agent.
The thiopurinemethyltransferase (TPMT) gene, codes for a key
enzyme in the metabolism of 6-MP (Figure 1) and other related
thiopurine drugs such as 6-thioguanine and azathioprine. This
enzyme is affected by functional polymorphisms that have been
shown to produce a defective enzyme, amongst them, TPMT*2
(G238C), TMPT*3A (G460A, A719G), and TPMT*3C (A719G)
account for 90% of the enzymatic deﬁciency in most popula-
tions (Weinshilboum, 2001). Approximately one in 300 hundred
individuals are homozygous for these variants and therefore lack
TPMT activity, which results in high levels of 6-TGN and acute
hematopoietic toxic effects, greater risk for radiation-induced
brain tumors and a greater likelihood of chemotherapy-induced
acute myeloid leukemia (Pui et al., 2004). Because of this, extreme
caution should be exerted in those children with ALL who lack
TPMT activity and are scheduled to receive 6-MP. In turn, these
subjects are far less prone to experience a relapse (Lennard and
Lilleyman, 1996). Dose reductions of up to 90% have been proved
useful in these patients (McLeod et al., 2000). For heterozygous
carriers the administration of 50% of the standard dose is recom-
mended, although there has been a certain degree of controversy
as to whether these patients with intermediate activity may beneﬁt
from lower doses (McLeod et al., 1999; Stanulla et al., 2005).
Having said that, theTPMT polymorphism does not explain all
6-MP-induced adverse effects, and some severe toxicities leading
to life-threatening conditions remain unexplained (Palmieri et al.,
2007). Additional SNPs in genes encoding enzymes involved in
6-MP metabolism and transport might contribute to the drug-
induced toxicity. This is the case of the inosine triphosphate
pyrophosphatase (ITPA) enzyme, which catalyzes one of the
intermediate steps of 6-MP metabolism (Figure 1). Two SNPs
in the ITPA gene with a frequency of roughly 10% in Cau-
casians (Adam de Beaumais and Jacqz-Aigrain, 2012), namely
a non-synonymous C94A transition (rs1127354, Pro32Thr) and
the intronic IVS2 + 21A > C mutation have been related with
defective enzyme activity (Heller et al., 2004) leading to higher
risk of myelotoxicity and hepatotoxicity in ALL pediatric patients
(Hawwa et al., 2008; Stocco et al., 2009; Wan Rosalina et al., 2011).
FIGURE 1 | 6-mercaptopurine (6-MP) intracellular pathways with
polymorphisms suggested to increase the occurrence of adverse effects.
SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; TPMT,
thiopurine S-methyltransferase; XO, xanthine oxidase; 6-Me-MP,
6-methyl-mercaptopurine; 6-TIMP, 6-thioinosine monophosphate; 6-TITP,
6-thioinosine triphosphate; ITPA, inosine triphosphate pyrophosphatase;
6-MMPN, 6-methyl-mercaptopurine nucleotides; 6-TGN, 6-thioguanine
nucleotides
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In addition, MTHFR SNPs have been shown to be more common
in subjects with low TPMT activity (Karas-Kuzelicki et al., 2009),
probably because of their impact on S-adenosylmethionine, which
functions as a cofactor for TPMT. Other polymorphisms in genes
involved in 6-MP disposition such as xanthine oxidase or ABCC4
have also been suggested to impact clinical outcomes, although
there are as yet no available data in ALL patients (Hawwa et al.,
2008; Ban et al., 2010).
The use of the TPMT genotyping for tailoringALL therapy, and
the putative inclusion of other polymorphisms in these genetic
tests will be discussed in the ﬁnal chapter of this review.
METHOTREXATE
Methotrexate (MTX) is a folate inhibitor widely employed in
the chemotherapy of hematologic malignancies and various solid
tumors. This drug is the cornerstone for therapy of ALL and has
been the focus of a number of pharmacogenetic studies aimed to
identify genetic determinants of its toxicity (reviewed elsewhere
Gervasini, 2009). Its actions on folate metabolism follow a com-
plex pattern that includes several transporters and metabolizing
enzymes whose function and/or expression have been suggested
to be altered by genetic polymorphisms.
Brieﬂy, the reduced folate carrier 1 (RFC1, SLC19A1) is respon-
sible for the entry of MTX in the cell (Moscow et al., 1995), whilst
the drug is pumped out by a variety of ATP-binding cassette
(ABC) efﬂux transporters (Strand et al., 1999). In the cell, MTX
is metabolized to active polyglutamates, which are responsible
for the disruption of the folate metabolic pathway by inhibiting
enzymes that are essential for the DNA (Chabner et al., 1985).
These include thymidylate synthase (TS; Szeto et al., 1979) and
dihydrofolate reductase (DHFR; Galivan, 1980). Another key
enzyme in the folate pathways is methylenetetrahydrofolate reduc-
tase (MTHFR), which produces 5-methyl-tetrahydrofolate (THF)
from 5,10-methylene-THF, a major intermediary that is in turn
synthesizedby serinehydroxymethyltransferase (SHMT1). Finally,
the production of 5-methyl-THF is pivotal for biotransforma-
tion of homocysteine to methionine, which involves two major
enzymes, namely methionine synthase (MS) and methionine syn-
thase reductase (MTRR). Figure 2 depicts an overview of these
intracellular pathways pointing out those SNPs that have been
related with the occurrence of MTX-induced toxicity.
MTHFR has by far been the most extensively studied gene in
association studies in ALL. Two SNPs, C677T (rs1801133) and
A1298C (rs1801131), have been related to increased MTX toxic-
ity (Kantar et al., 2009; D’Angelo et al., 2011). However, a recent
meta-analysis (Yang et al., 2012), as well as the general perception
in the literature (reviewed by Gervasini, 2009) lead to think that
C677T is the only SNP that plays a clinically signiﬁcant role, albeit
contradictory results also exist (Chatzidakis et al., 2006; Kishi et al.,
2007; Huang et al., 2008).
FIGURE 2 | Overview of methotrexate (MTX) mechanisms of
action in the folate metabolic pathway. Clinically signiﬁcant
polymorphisms are shown for the main genes involved. MTX-PG,
methotrexate polyglutamates; SLC19A1, solute carrier 19A1; ABCC1
and 2, ATP-binding cassette C1 and 2 transporters; ABCG2, ATP-binding
cassette G2 transporter, breast cancer resistance protein; ABCB1,
ATP-binding cassette B1 transporter, multidrug resistance; FPGS,
folylpolyglutamyl synthase; GGH, γ-glutamyl hydrolase;TS, thymidylate
synthase; UTR, untranslated region; DHFR, dihydrofolate reductase; SHMT,
serine hydroxymethyltransferase; MTHFD1, methylenetetrahydrofolate
dehydrogenase; CCND1, cyclin D1; ATIC, aminoimidazole 4-carboxamide
ribonucleotide (AICAR) transformylase; MS, methionine synthase; MTRR,
methionine synthase reductase. Adapted with permission from
Gervasini (2009).
Frontiers in Genetics | Pharmacogenetics and Pharmacogenomics November 2012 | Volume 3 | Article 249 | 6
“fgene-03-00249” — 2012/11/20 — 21:12 — page 7 — #7
Gervasini and Vagace Genetic polymorphisms in acute leukemia
Most notably, given the severity of the syndrome, the 677T allele
has been suggested to induce MTX-related neurotoxicity (mainly
subacute leukoencephalopathy) in young ALL patients (Strunk
et al., 2003; Mahadeo et al., 2010; Vagace et al., 2011, 2012). It
should be noted that this association has only been observed in
clinical case reports. In fact, a study in 53 childrenwithALL treated
with high-dose MTX failed to conﬁrm a relevant role of the 677T
allele in the drug-induced neurotoxicity developed by nine of the
patients (Kishi et al., 2003). In order to elucidate this controversy,
it would be desirable to genotype large populations of pediatric
ALL patients who underwent MTX-related neurotoxicity. How-
ever, the lack of homogeneity of treatment protocols, which makes
multicenter studies hard to conduct, the low number of patients
affected, and the more than likely inﬂuence of other SNPs, have so
far been insurmountable obstacles.
A 19 bp ins/del polymorphism in the DHFR gene has also
been associated with increased toxicity in adult leukemia patients
treated with MTX (Ongaro et al., 2009). In the same manner, the
MTRR A66G SNP has been related to increased risk of develop-
ing toxicity in children with ALL treated with high doses of MTX
(Huang et al., 2008), although there seems to be no relation with
CNS side effects (Krajinovic et al., 2005).
Other genes that could also be involved in the development
of MTX-induced toxicity are the ABC efﬂux transporters. Their
location in the blood-brain barrier makes tempting to speculate
that polymorphisms in these genes could lead to drug accumula-
tion in the brain and subsequent neurotoxicity. For instance, the
combined presence of the C421A (rs2231142, Gln141Lys) SNP
in the ABCG2 gene (encoding the Breast Resistance Cancer Pro-
tein, BCRP transporter) and the C3435T transition in ABCB1
(coding for P-glycoprotein) has been related to the occurrence
of encephalopathy in children with ALL treated with MTX (Erdi-
lyi et al., 2008). Finally, the G-80A polymorphism in the RFC1
inﬂux transporter, which determines intracellular levels of MTX,
has been associated with increased overall toxicity in ALL patients
(Shimasaki et al., 2006; Imanishi et al., 2007; Kishi et al., 2007).
It should be noted that large studies on the association between
MTX toxicity and genetics in childhood ALL are still scarce and
mostly focus on MTHFR variants. Studies carried out in other
pathologies have found evidences of increased toxicity in the pres-
ence of variant alleles in additional ABC transporters (Campalani
et al., 2007; Ranganathan et al., 2008), or in the SHMT1 (Weisman
et al., 2006) and TS genes (Campalani et al., 2007). Therefore, we
should not rule out the implication of these polymorphisms in
MXT-related side effects experienced by ALL patients.
VINCRISTINE
The wide pharmacokinetic interindividual variability shown by
vincristine, and the occurrence of its dose-limiting neurotoxicity
remains largely unpredictable (Moore and Pinkerton, 2009). Ren-
barger et al. (2008) have showed different grades of neurotoxicity
in Caucasians compared to African Americans, suggesting that
genetics could inﬂuence vincristine-induced toxicity.
The main candidate gene for pharmacogenetic studies is
CYP3A5, since it is known to contribute between 55 and 95%
to total vincristine metabolism (Dennison et al., 2006). In addi-
tion, the drug is a substrate for P-glycoprotein (Song et al., 1999),
which makes the encoding ABCB1 gene another suitable candi-
date for pharmacogenetic studies. Two reports have evaluated the
clinical effect of common SNPs (CYP3A5*3 and ABCB1 C3435T
and G2677T) in these genes in pediatric ALL patients treated
with vincristine. However, the authors failed to ﬁnd a signiﬁ-
cant association with increased occurrence of side effects such as
impaired motor activity or constipation (Plasschaert et al., 2004;
Hartman et al., 2010).These two studies combined added up to
only 86 genotyped patients, which is clearly not sufﬁcient to
rule out the involvement of these candidate genes in vincristine
toxicity.
PERSPECTIVES AND CONCLUSION
The utility of pharmacogenetics in clinical routine has turned to
be lower than anticipated, as numerous barriers to implementing
individualized medicine have appeared over the years (Agundez
et al., 2012). Cases in which a genetic test is sufﬁcient to sig-
niﬁcantly affect a given therapy are discouragingly uncommon
(Groenen, 2011) and the leukemia setting is not an exception.
Indeed, only 1–2% of marketed drugs have pharmacogenomic-
based recommendations (Agundez et al., 2012) and amongst the
drugs commonly used in the chemotherapy of pediatric ALL, only
6-MP, thioguanine and azathioprine labels include genetic test-
ing (TPMT) as a recommendation to help individualize therapy.
However, steps are being taken in order to revert this situation.
The increasing availability of low-cost, high-throughput genetic
platforms that allow the simultaneous screening of hundreds
of polymorphisms, the education of health practitioners or the
implementation of multicenter networks aimed to improve the
safety of new drugs, are some of the measures that hopefully will
help improve the impact of pharmacogenetics on clinical routine.
It should also be pointed out that genetic variability in several of
the targets for which genetic testing is recommended by the FDA
and other corporations has been shown to modify the risk of acute
leukemia (Agundez, 2004), which certainly enhances the utility of
these tests.
The body of work on the clinical impact of TPMT and MTHFR
polymorphisms on ALL does not mirror the limited current
knowledge on the pharmacogenetics of the other drugs that consti-
tute the core of chemotherapy for this disease. Thus, signiﬁcantly
less information is available with regard to vincristine, asparag-
inase, cyclophosphamide etc. The TPMT gene polymorphism
provides the best example of the value of applied pharmacoge-
netics in ALL and clinical oncology in general. It is now widely
acknowledged that the initial dose of 6-MP treatment should be
based on the TPMT genotype (Relling et al., 2011), thus allow-
ing the clinician to identify patients at higher risk of toxicity.
However, as it was described in the 6-MP chapter, there is still
some interindividual variability in the response to this drug that
cannot be explained only by the TPMT genotype (Palmieri et al.,
2007). Therefore, the implementation of additional genetic anal-
yses to identify polymorphisms in the ITPA, MTHFR, XO and
other genes in the 6-MP intracellular pathway, as well as the study
of their epistatic interactions seem to be reasonable steps to take in
order to better adjust 6-MP doses in ALL patients. Furthermore,
pharmacogenomics alone may not be sufﬁcient to explain all the
interindividual variability in 6-MP response and efforts should be
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undertaken in the coming years to create more precise algorithms
that can help predict drug response.
With regard to MTHFR, the reasons for the present controversy
regarding the inﬂuence of its genetic variation on MTX-induced
toxicity are diverse. For instance, the wide variety of diseases in
which MTX has been proved useful has paradoxically hampered
the reproducibility of the results of genetic association studies,
because of the heterogeneity of the patients analyzed. Moreover,
other unknown variants in the same gene, epistatic interactions
with other genes and,most likely, the combination of these factors,
may result in genetic backgrounds with different susceptibilities
to MTX-induced toxicity. The challenge seems to be to iden-
tify which genetic factors and genetic combinations are those in
speciﬁc populations.
Some ALL chemotherapy regimens contemplate MTX dose
reductions for subjects homozygous for the 677T variant or for
those carrying both 677CT and 1298AC heterozygous genotypes.
One could consider at least premature to make this kind of dose
adjustments based on data that are still controversial. In fact,
MTX was not included in the list of drugs mentioned in the
Table of Pharmacogenomic Biomarkers in Drug Label issued by the
Food and Drug Administration (FDA) last year (FDA, 2011). It is
probably naive to believe that the determination of SNPs in just
one gene (MTHFR) belonging to a highly complex intracellular
pathway, such as that of MTX, is enough to accurately anticipate
the occurrence of adverse effects.
As a general rule, it would be logical to think that the iden-
tiﬁcation of combinations of mutations in several genes along
the pathway of a given drug must be more helpful in terms of
identifying subjects at-risk of toxicity than a single-SNP approach
(Vagace et al., 2011). This is crucial in the case of drugs with
intricate intracellular routes as it is the case of MTX or 6-MP.
Genome-wide approaches such as the ones reported by (Huang
et al., 2007), Bleibel et al. (2009), and Chen et al. (2011) are able
to evaluate whole pathways to identify key routes that can be
later studied in detail. In addition, the inclusion of other clini-
cal and demographic factors may increase the predictive value of
pharmacogenetic models (Wessels et al., 2007).
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